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The c-Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) has been proposed to act as a scaffold
protein that mediates JNK activation. However, recent studies have implicated JIP1 in multiple biochemical
processes. Physiological roles of JIP1 that are related to the JNK scaffold function of JIP1 are therefore
unclear. To test the role of JIP1 in JNK activation, we created mice with a germ line point mutation in the Jip1
gene (Thr103 replaced with Ala) that selectively blocks JIP1-mediated JNK activation. These mutant mice
exhibit a severe defect in JNK activation caused by feeding of a high-fat diet. The loss of JIP1-mediated JNK
activation protected the mutant mice against obesity-induced insulin resistance. We conclude that JIP1-
mediated JNK activation plays a critical role in metabolic stress regulation of the JNK signaling pathway.
Diet-induced obesity causes insulin resistance and metabolic
syndrome, which can lead to -cell dysfunction and type 2
diabetes (15). It is established that feeding mice a high-fat diet
(HFD) causes activation of c-Jun NH2-terminal kinase 1
(JNK1) (10). Moreover, Jnk1/ mice are protected against
the effects of HFD-induced insulin resistance (10). Together,
these observations indicate that JNK1 plays a critical role in
the metabolic stress response. However, the mechanism that
accounts for HFD-induced JNK1 activation is unclear. Recent
studies have implicated the JIP1 scaffold protein in JNK1 ac-
tivation caused by metabolic stress (23, 39).
JIP1 can assemble a functional JNK activation module com-
posed of a mitogen-activated protein kinase (MAPK) kinase
kinase (a member of the mixed-lineage protein kinase [MLK]
group), the MAPK kinase MKK7, and JNK (40, 42). This
complex may be relevant to JNK activation caused by meta-
bolic stress (23, 39). Indeed, MLK-deficient mice (14) and
JIP1-deficient mice (13) exhibit defects in HFD-induced JNK
activation and insulin resistance.
The protection of Jip1/ mice against the effects of being
fed an HFD may be mediated by loss of the JNK scaffold
function of JIP1. However, JIP1 has also been reported to
mediate other biochemical processes that would also be dis-
rupted in Jip1/ mice. For example, JIP1 interacts with AKT
and has been implicated in the mechanism of AKT activation
(8, 17, 18, 34). Moreover, JIP1 interacts with members of the
Src and Abl tyrosine kinase families (4, 16, 24), the lipid phos-
phatase SHIP2 (44), the MAPK phosphatase MKP7 (43),
-amyloid precursor protein (20, 31), the small GTPase regu-
latory proteins Ras-GRF1, p190-RhoGEF, RalGDS, and
Tiam1 (2, 8, 21), ankyrin G (35), molecular chaperones (35),
and the low-density-lipoprotein-related receptors LRP1,
LRP2, and LRP8 (7, 37). JIP1 also interacts with other scaffold
proteins, including the insulin receptor substrate proteins IRS1
and IRS2 (35). Finally, JIP1 may act as an adapter protein for
kinesin-mediated (11, 12, 16, 38, 42) and dynein-mediated (35)
trafficking on microtubules. The JNK scaffold properties of
JIP1 therefore represent only one of the possible biochemical
functions of JIP1 that are disrupted in Jip1/ mice.
The purpose of this study was to test the role of JIP1 as a
JNK scaffold protein in the response of mice to being fed an
HFD. Our approach was to examine the effect of a point
mutation that selectively prevents JIP1-induced JNK activa-
tion. It is established that phosphorylation of JIP1 on Thr103 is
required for JIP1-mediated JNK activation by the MLK
pathway (25). Consequently, the phosphorylation-defective
Thr103Ala JIP1 protein does not activate JNK (25). Here we
describe the analysis of mice with a point mutation in the Jip1
gene that replaces the JIP1 phosphorylation site Thr103 with
Ala. We show that this mutation suppresses HFD-induced
JNK activation and insulin resistance. These data demonstrate
that JNK activation mediated by the JIP1 scaffold complex
contributes to the response of mice to an HFD.
MATERIALS AND METHODS
Mice. Mice with a point mutation in JIP1 (Thr103Ala) were constructed by
homologous recombination in embryonic stem (ES) cells using standard methods
(see Fig. 1). Briefly, a targeting vector was constructed (see Fig. 1). This targeting
vector was designed to introduce point mutations in exon 3 of the Jip1 gene that
create the Th103Ala mutation and also a novel XmaI restriction site (see Fig. 1).
TC1 embryonic stem cells (strain 129svev) were electroporated with this vector
and selected with 200 g/ml G418 (Invitrogen) and 2 M ganciclovir (Syntex).
Correctly targeted ES cell clones were identified by Southern blot analysis and
were injected into C57BL/6J blastocysts to create chimeric mice that were bred
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FIG. 1. Creation of mice with a germ line knock-in mutation in the Jip1 gene. (A) Schematic illustration of the gene targeting strategy. A floxed
NeoR cassette was inserted into intron 3 of the Jip1 gene by homologous recombination. Point mutations were introduced into exon 3. The NeoR
cassette was excised using Cre recombinase. HindIII restriction sites are indicated (H). (B) The DNA sequence of the region of exon 3 of the Jip1
gene that surrounds codon 103 is presented. The mutated allele replaces codon 103, which encodes Thr (ACT) with Ala (GCC). Translationally
silent mutations were also introduced to create an XmaI restriction site in the mutated Jip1 allele (Jip1TA). (C) Genomic DNA was prepared from
wild-type (Jip1/) mice, heterozygous (Jip1/TA), and homozygous (Jip1TA/TA) mice. Genotype analysis was performed by PCR. (D) Extracts
prepared from the cerebellum of Jip1/, Jip1/TA, and Jip1TA/TA mice were examined by immunoblot analysis by probing with antibodies to JIP1,
JIP2, and -tubulin. (E) The expression of Jip1 mRNA in white adipose tissue (WAT), brown adipose tissue (BAT), quadriceps muscle, and liver
of C57BL/6J mice was measured by quantitative RT-PCR analysis of mRNA. The relative mRNA expression was calculated by normalization of
the data to the amount of Gapdh mRNA in each sample (mean  SE; n  8).
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to obtain germ line transmission of the mutated Jip1 allele. The floxed Neor
cassette was excised using Cre recombinase. The mice used in this study were
backcrossed (10 generations) to the C57BL/6J strain (Jackson Laboratories).
Male mice (8 to 10 weeks old) were fed a chow diet or an HFD. The mice were
housed in a facility accredited by the American Association for Laboratory
Animal Care (AALAC). The Institutional Animal Care and Use Committee
(IACUC) of the University of Massachusetts approved all studies using animals.
Genotyping. The Jip1TA allele was detected using two different assays. First,
Southern blot analysis of HindIII-restricted genomic DNA was performed by
probing with a 500-bp fragment of the Jip1 gene that was isolated by PCR using
the primers 5-CACATCTTGTGTGCTCAATCCG-3 and 5-GTTCTGGCTT
CTGATACTGAACCC-3. The Jip1 and Jip1TA alleles were detected as 11.9-kb
and 6.6-kb bands, respectively. Second, a PCR assay was employed using the
primers 5-CCAAGTTGTGTGTGGAGAGCTTG-3 and 5-GCAGATGTTG
GAAGAAGCAC-3. The Jip1 and Jip1TA alleles were amplified to yield 400-
and 450-bp DNA fragments, respectively (see Fig. 1C).
RNA analysis. The expression of mRNA was examined by quantitative PCR
analysis using a 7500 Fast real-time PCR machine. TaqMan assays were
used to quantitate Foxo1 (Mm00490672_m1), G6p (Mm00839363_m1), Pck1
(Mm00440636_m1), Jip1 (Mm00501836_g1), Pgc1 (Mm00447183_m1), Gck
FIG. 2. Comparison of HFD-induced obesity in JIPWT and JIPTA mice. (A) Mice (8 to 10 weeks old) were fed either a chow diet (ND) or a
high-fat diet (HFD) for 16 weeks. The body weight of the mice was measured (mean  SE; n  10 to 15). No significant difference between the
weights of JIPWT and JIPTA mice was detected (P 	 0.05). (B) Fat and lean body mass of mice fed (3 weeks) a chow diet (ND) or an HFD (HF)
was measured by 1H-MRS. The data presented are the means  SE (n 8). No significant difference between JIPWT and JIPTA mice was detected
(P 	 0.05). (C) Chow-fed (ND) and HFD-fed (HF) mice (16 weeks) were fasted overnight. JNK1 activity in epididymal fat was measured in a
protein kinase (KA) assay using c-Jun and [
-32P]ATP as substrates. The cell extracts used for the protein kinase assay were also examined by
immunoblot analysis by probing with an antibody to JNK. Representative data are presented (upper panel) and quantitated (mean  SE [n  5])
(lower panel). Statistically significant differences are indicated (**, P 0.01). (D) Chow-fed (ND) and HFD-fed (HF) mice (16 weeks) were fasted
overnight. The blood glucose concentration was measured (mean  SE; n  10 to 15). Statistically significant differences are indicated (**, P 
0.01). (E) Chow-fed (ND) and HFD-fed (HF) mice (16 weeks) were fasted overnight. Epididymal fat was examined by immunoblot analysis by
probing with antibodies to phospho-Ser307 IRS1, IRS1, and tubulin. (F) Chow-fed (ND) and HFD-fed (HF) mice (16 weeks) were fasted overnight.
The blood insulin concentration was measured (mean  SE; n  10 to 15). Statistically significant differences are indicated (*, P  0.05).
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(Mm00439129_m1), Adiponectin (Mm00456425_m1), C/ebp (Mm00514283_s1),
C/ebp (Mm00843434_s1), Socs3 (Mm01249143_g1), and Vldlr (Mm00443298_m1)
(Applied Biosystems). The amount of Srebp1c mRNA was measured by quanti-
tative reverse transcription-PCR (RT-PCR) using Sybr green detection and the
amplimers GATGTGCGAACTGGACACCAG and CATAGGGGGCGTCAA
ACAG. The relative mRNA expression was normalized by measurement of the
amount of Gapdh RNA in each sample using TaqMan assays (4352339E-
0904021; Applied Biosystems).
Immunoblot analysis. Tissue extracts were prepared using Triton lysis buffer
(20 mM Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM
EDTA, 25 mM -glycerophosphate, 1 mM sodium orthovanadate, 1 mM phe-
nylmethylsulfonyl fluoride, and 10 g/ml of aprotinin and leupeptin). Extracts
(20 to 50 g of protein) were examined by protein immunoblot analysis by
probing with antibodies to AKT, phospho-Thr308 AKT, and phospho-Ser473
AKT (Cell Signaling), IRS1 (30), phospho-Ser307 IRS1 (Millipore), JNK1, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Santa Cruz). Immuno-
complexes were detected by enhanced chemiluminescence (NEN). We per-
formed quantitation using a multiplexed enzyme-linked immunosorbent assay
(ELISA) (Luminex 200 machine; Millipore).
Measurement of blood glucose, adipokine, cytokine, and insulin concentra-
tion. Blood glucose was measured using an Ascensia Breeze 2 glucometer
(Bayer). Adipokines, cytokines, and insulin in plasma were measured by ELISA
using a Luminex 200 machine (Millipore).
Glucose and insulin tolerance tests. The mice were fed a standard chow diet
or a high-fat diet (Iso Pro 3000, Purina, and F3282; Bioserve Inc.) for 16 weeks.
Glucose tolerance and insulin tolerance tests were performed using methods
described previously (22).
Blood lipid analysis. Triglyceride was measured using a kit purchased from
Sigma.
Measurement of hepatic triglyceride. Hepatic triglyceride content was mea-
sured using livers from overnight-fasted mice. Total lipids were extracted from
liver samples (50 mg) using an 8:1 mixture of chloroform and methanol (4 h).
The extracts were mixed with 1 N sulfuric acid and centrifuged (10 min). The
amount of triglyceride was measured using a kit purchased from Sigma.
Protein kinase assays. JNK activity was measured using an in vitro protein
kinase assay with the substrates c-Jun and [
-32P]ATP (41).
Hyperinsulinemic-euglycemic clamp studies. Clamp studies were performed
at the UMASS Mouse Phenotyping Center. Briefly, mice were fed an HFD (55%
fat by calories; Harlan Teklad) or a chow diet for 4 weeks, and whole-body fat
and lean mass were noninvasively measured using proton magnetic resonance
spectroscopy (1H-MRS) (Echo Medical Systems). Following an overnight fast, a
2-h hyperinsulinemic-euglycemic clamp was conducted in conscious mice with a
primed and continuous infusion of human insulin (150 mU/kg body weight
priming, followed by 2.5 mU/kg/min; Humulin; Eli Lilly), and 20% glucose was
infused at various rates to maintain euglycemia (19). Whole-body glucose turn-
over was assessed with a continuous infusion of [3-3H]glucose, and 2-deoxy-D-
[1-14C]glucose (PerkinElmer) was administered as a bolus (10 Ci) at 75 min
after the start of clamps to measure insulin-stimulated glucose uptake in indi-
vidual organs. At the end of the clamps, mice were anesthetized and tissues were
taken for biochemical analysis (19).
Analysis of tissue sections. Histology was performed using tissue fixed in 10%
formalin for 24 h, dehydrated, and embedded in paraffin. Sections (7 m) were
cut and stained using hematoxylin and eosin (American Master Tech Scientific).
Frozen sections of liver (5 m) prepared using tissue frozen in O.C.T. compound
(Tissue-Tek) were stained using Sudan Black B according to the manufacturer’s
protocol (American Master Tech Scientific).
Statistical analysis. Differences between groups were examined for statistical
significance using the Student test or analysis of variance (ANOVA) with Fish-
er’s test.
RESULTS
To examine the role of JIP1 as a scaffold protein for the JNK
signaling pathway, we investigated the effect of a JIP1 point
mutation (Thr103 replaced with Ala) that selectively blocks
JIP1-mediated JNK activation (25). We created mice with a
germ line mutation in exon 3 of the Jip1 gene that modifies
codon 103 (ACT replaced with GCC) and encodes a mutant
Thr103Ala JIP1 protein (Fig. 1). The mutant mice were back-
crossed to the C57BL/6J strain (10 generations). Heterozygous
matings resulted in wild-type, heterozygous, and homozygous
mutant mice in the expected Mendelian ratios. The homozy-
gous mutant (JIP1TA) mice were viable and fertile. Compari-
son of wild-type (JIP1WT) and JIP1TA mice demonstrated that
the Thr103Ala mutation did not affect the amount of JIP1
protein detected by immunoblot analysis (Fig. 1).
HFD-induced JNK1 activation in JIP1WT and JIP1TA mice.
We examined the effect of feeding an HFD to JIP1WT and
JIP1TA mice. The Thr103Ala point mutation caused no change
in HFD-induced weight gain (Fig. 2A). Measurement of
whole-body lean and fat mass by 1H-MRS confirmed that the
FIG. 3. Comparison of the responses of JIPWT and JIPTA mice to
glucose and insulin tolerance tests. (A) Glucose tolerance tests (GTT)
with chow-fed (ND) and HFD-fed JIPWT and JIPTA mice (16 weeks)
were performed by measurement of blood glucose concentrations in
animals following intraperitoneal injection of glucose (1 g/kg). The
data presented represent the means  SE (n  10 to 15). No statis-
tically significant differences between JIPWT and JIPTA mice were
detected (P	 0.05). (B) Glucose-induced insulin release. The effect of
administration of glucose (2 g/kg body mass) by intraperitoneal injec-
tion on the blood insulin concentration was examined (means  SE;
n  13 to 15). Statistically significant differences between JIPWT and
JIPTTA mice are indicated (*, P  0.05). (C) Insulin tolerance tests
(ITT) with JIPWT and JIPTA mice fed either a chow diet (ND) or an
HFD for 16 weeks were performed by intraperitoneal injection of
insulin (1.5 U/kg body mass). The concentration of blood glucose was
measured (mean  SE; n  10). Statistically significant differences
between JIPWT and JIPTTA mice are indicated (*, P  0.05; **, P 
0.01).
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wild-type and mutant mice exhibited HFD-induced obesity
(Fig. 2B). Importantly, the HFD-induced weight gain by
JIP1WT and JIP1TA mice indicates that these mice mount re-
sponses to a similar stress-related insult when fed an HFD.
Measurement of JNK1 activity in epididymal adipose tissue
demonstrated that HFD-induced JNK1 activation in JIP1WT
mice was markedly suppressed in JIP1TA mice (Fig. 2C). To
test whether the reduced HFD-induced JNK1 activation was
physiologically significant, we examined the phosphorylation of
the JNK1 substrate IRS1. We found that JNK1-mediated
phosphorylation of IRS1 on Ser307 was reduced in HFD-fed
JIP1TA mice compared with that in HFD-fed JIP1WT mice
(Fig. 2E). These observations demonstrate that JNK activation
caused by feeding an HFD is mediated by the JIP1 scaffold
protein pathway.
JIP1TA mice exhibit increased insulin sensitivity. The hy-
perglycemia and hyperinsulinemia found in HFD-fed JIP1WT
mice were significantly reduced in HFD-fed JIP1TA mice (Fig.
2D and F). We performed glucose tolerance tests (GTT) to
compare the responses of JIP1WT and JIP1TA mice to a glu-
cose challenge. We found that feeding an HFD caused similar
glucose intolerance in JIP1WT and JIP1TA mice (Fig. 3A). This
glucose intolerance was caused in part by decreased glucose-
induced insulin release. Indeed, no significant differences in
glucose-induced insulin release between HFD-fed JIP1WT
mice and HFD-fed JIP1TA mice were detected (Fig. 3B). In
contrast, insulin tolerance tests (ITT) demonstrated that insu-
FIG. 4. Effect of the Thr103Ala JIP1 mutation on insulin sensitivity. Insulin sensitivity was measured using a hyperinsulinemic-euglycemic
clamp in conscious chow-fed (ND) and HFD-fed (HF) JIP1WT and JIP1TA mice. The data presented are the means  SE for 8 or 9 experiments.
Statistically significant differences between JIP1WT and JIP1TA mice are indicated (*, P  0.05). (A) Steady-state glucose infusion rate during the
clamp. (B) Hepatic glucose production (HGP) during the clamp. (C) Hepatic insulin action, expressed as insulin-mediated percent suppression of
basal HGP. (D) Insulin-stimulated whole-body glucose turnover. (E) Whole-body glycogen plus lipid synthesis. (F) Whole-body glycolysis.
FIG. 5. Increased insulin sensitivity of HFD-fed JIP1TA mice com-
pared with that of HFD-fed JIP1TA mice. (A) Chow-fed (ND) and HFD-
fed (HF) JIP1WT and JIP1TA mice (16 weeks) were fasted overnight and
then treated by intraperitoneal injection of 1.5 U/kg insulin. Extracts prepared
from epididymal fat pads at 10 min postinjection were examined by immu-
noblot analysis using antibodies to phospho-AKT (Thr308 and Ser473), AKT,
and GAPDH. (B) Quantitative analysis of AKT phosphorylation (Ser473) was
performed by ELISA (Luminex 200 machine). The relative AKT phosphor-
ylation is presented (mean  SE; n  5 to 8). Ins, insulin.
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lin-induced disposal of blood glucose was significantly in-
creased in HFD-fed JIP1TA mice over that in HFD-fed JIP1WT
mice (Fig. 3C). These data suggest that the Thr103Ala muta-
tion in JIP1 increased insulin sensitivity in HFD-fed mice.
To confirm the initial observation that JIP1TA mice are more
insulin sensitive, we conducted a hyperinsulinemic-euglycemic
clamp study in conscious mice. The steady-state glucose infu-
sion rates during the clamp were significantly greater in JIP1TA
mice than in JIP1WT mice (Fig. 4A), indicating that JIP1TA
mice were more insulin sensitive than JIP1WT mice. Indeed,
FIG. 6. The Thr103Ala JIP1 mutation reduces HFD-induced hepatic steatosis. (A) Sections prepared from chow-fed (ND) and HFD-fed (HF)
JIP1WT and JIP1TA mice (16 weeks) were stained with hematoxylin and eosin (H&E) or with Sudan Black B. Scale bar  100 m. (B) The liver
mass at the time of necropsy (16 weeks) is presented (mean  SE; n  10). Statistically significant differences between JIP1WT and JIP1TA mice
are indicated (*, P  0.05). (C and D) The amount of hepatic or blood triglycerides was measured (mean  SE; n  10). Statistically significant
differences between JIP1WT and JIP1TA mice are indicated (*, P 0.05; **, P 0.01). (E to G) The amount of C/ebp, C/ebp, or Srebp1c mRNA
in the liver of JIP1WT and JIP1TA mice was measured by quantitative RT-PCR and was normalized to the amount of Gapdh mRNA in each sample
(mean SE; n 8). Statistically significant differences between JIP1WT and JIP1TA mice are indicated (*, P 0.05; **, P 0.01; ***, P 0.001)).
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hepatic glucose production (HGP) during the clamp was sig-
nificantly decreased in JIP1TA mice compared with that in
JIP1WT mice (Fig. 4B). Basal HGP was not significantly altered
between the groups. These data demonstrate that JIP1TA mice
exhibit increased hepatic insulin action compared with that of
JIP1WT mice (Fig. 4C). Feeding an HFD caused hepatic insu-
lin resistance, but HFD-fed JIP1TA mice exhibited increased
insulin sensitivity compared with HFD-fed JIP1WT mice (Fig.
4C). No significant differences between JIP1WT mice and
JIP1TA mice in insulin-stimulated whole-body glucose turnover
and glucose metabolic fluxes (glycolysis and glycogen plus lipid
synthesis) were detected (Fig. 4D to F). Together, these data
demonstrate that JIP1TA mice are more insulin sensitive than
JIP1WT mice.
To obtain biochemical evidence for insulin sensitivity, we
examined insulin-stimulated AKT activation in adipose tissue
of JIP1WT and JIP1TA mice (Fig. 5). Insulin treatment of
chow-fed JIP1WT and JIP1TA mice caused increased AKT ac-
tivation. Feeding an HFD suppressed insulin-stimulated AKT
activation in JIP1WT mice (Fig. 5). In contrast, the HFD did
not suppress insulin-stimulated AKT activation in JIP1TA mice
(Fig. 5). These data support the conclusion that JIP1TA mice
exhibit protection against HFD-induced insulin resistance.
JIP1TA mice are protected against HFD-induced hepatic
steatosis. Feeding an HFD to JIP1WT mice caused morpho-
logical changes in the liver, including an increase in mass and
accumulation of triglyceride (Fig. 6A to C). These changes
were markedly suppressed in JIP1TA mice (Fig. 6A to C). The
reduced accumulation of hepatic lipid in HFD-fed JIP1TA
mice compared with that in HFD-fed JIP1WT mice was asso-
ciated with decreased expression of lipogenic transcription fac-
tors (C/ebp, C/ebp, and Srebp1c) (Fig. 6E to G). These
observations are consistent with a reduction in triglyceride
accumulation in the liver (Fig. 6A and C) and blood (Fig. 6D).
Together, these data demonstrate that JIP1TA mice exhibit
protection against HFD-induced hepatic steatosis.
We examined JIP1WT and JIP1TA mice in metabolic cages to
investigate possible mechanisms that might contribute to the
reduced steatosis of JIP1TA mice compared with that in
JIP1WT mice (Fig. 7). The daily food intake by chow-fed
JIP1WT and JIP1TA mice was similar, but a moderate decrease
in food intake by HFD-fed JIP1TA mice compared with that by
HFD-fed JIP1WT mice was detected (Fig. 7B). No significant
differences between JIP1WT and JIP1TA mice in O2 consump-
tion, CO2 production, energy expenditure, and physical activity
were detected (Fig. 7C to F). However, the respiratory ex-
change quotient (RQ) ([VCO2]/[VO2]) of JIP1
TA mice was sig-
nificantly decreased compared with that of JIP1WT mice (Fig.
7G). These data indicate that fat oxidation by JIP1TA mice is
increased over that by JIP1WT mice. Together, the decreased
food intake and increased fat oxidation may contribute to the
suppression of hepatic steatosis in JIP1TA mice compared with
JIP1WT mice.
Mechanism of protection against HFD-induced hepatic in-
sulin resistance in JIP1TA mice. The protection of adipose
tissue in JIP1TA mice against HFD-induced insulin resistance
(Fig. 5) may result from reduced HFD-induced JNK1 activa-
tion (Fig. 2C and E). This conclusion is consistent with the
finding that adipose tissue-specific JNK1 knockout mice ex-
hibit protection against HFD-induced adipose tissue insulin
resistance (30). In contrast, the mechanism of protection of
FIG. 7. Comparison of energy balance of JIPWT and JIPTA mice using metabolic cages. (A to G) Groups of 6 mice were examined during a
3-day period to measure the mean food and water consumption, gas exchange (VO2 and VCO2), respiratory exchange quotient [VCO2]/[VO2], energy
expenditure, and physical activity. Statistically significant differences between JIPWT and JIPTA mice are indicated (*, P  0.05; **, P  0.01).
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HFD-fed JIP1TA mice against HFD-induced hepatic insulin
resistance is unclear (Fig. 4C).
Two observations complicate the interpretation of the effect
of the Thr103Ala JIP1 mutation on the response of the liver to
feeding of an HFD. First, liver-specific JNK1 knockout mice
are not protected against HFD-induced hepatic insulin resis-
tance (29). The effects of JIP1 on the liver may therefore not
be mediated by hepatic JNK1. Second, JIP1 is expressed by
white adipose tissue and brown adipose tissue, but JIP1 is
expressed only at very low levels in the liver (Fig. 1E). It is
therefore unclear that the effects of JIP1 on the liver are
mediated by a cell autonomous mechanism.
We have previously reported that adipose JNK1 can regu-
late hepatic insulin sensitivity by a mechanism that involves
JNK1-dependent expression of interleukin 6 (IL-6) by adipose
tissue and subsequent IL-6-induced SOCS3-mediated inhibi-
tion of hepatic insulin receptor signaling (30). This mechanism
could account for JIP1-mediated regulation of hepatic insulin
resistance. Indeed, the HFD-induced activation of JNK1 in
adipose tissue (Fig. 2C) and the increase in the blood IL-6
concentration (Fig. 8A) observed in JIP1WT mice were mark-
edly reduced in JIP1TA mice. Control studies demonstrated
that the Thr103Ala JIP1 mutation caused no change in the
blood concentration of tumor necrosis factor  (TNF-) (Fig.
8B). However, the blood concentrations of leptin and resistin
were decreased in HFD-fed JIP1TA mice (Fig. 9A and B) and
the expression of adiponectin was increased (Fig. 9C) com-
pared with those in HFD-fed JIP1WT mice. These changes in
blood adipokines may also contribute to the hepatic insulin
sensitivity of HFD-fed JIP1TA mice.
To test whether suppression of HFD-induced expression of
IL-6 in the blood of JIP1TA mice contributes to the metabolic
phenotype of JIP1TA mice, we examined the expression of IL-6
target genes in the liver, including suppressor of cytokine sig-
naling 3 (Socs3) (36) and very low density lipoprotein receptor
(Vldlr) (9). Feeding an HFD to JIP1WT mice but not JIP1TA
mice caused increased expression of Socs3 (Fig. 8C and E) and
Vldlr (Fig. 8D). These data demonstrate that JIP1TA mice
exhibit a marked defect in HFD-induced activation of the
hepatic IL-6 signal transduction pathway in vivo. Since IL-6-
induced SOCS3 expression can cause hepatic insulin resistance
(5, 6, 26, 30, 32, 33), reduced expression of SOCS3 in liver may
contribute to the increased hepatic insulin sensitivity of HFD-
fed JIP1TA mice.
DISCUSSION
The JIP1 protein is implicated in HFD-induced JNK activa-
tion (23, 39). Indeed, Jip1/ mice exhibit a major defect in
HFD-induced JNK activation and insulin resistance (13), and
it is established that the JIP1 protein can assemble a functional
JNK signaling module (40, 42). However, JIP1 appears to be a
multifunctional protein that may have additional biological
activities (23). Thus, JIP1 may act as an adapter protein for
kinesin-mediated (11, 12, 16, 38, 42) and dynein-mediated (35)
trafficking on microtubules. It is not known whether this pro-
posed transport function of JIP1 might contribute to HFD-
induced insulin resistance. However, other proposed functions
of JIP1, including interactions with AKT and insulin receptor
substrate proteins (8, 17, 18, 34, 35), may contribute to HFD-
induced insulin resistance. The mechanism that accounts for
the effect of JIP1 deficiency to protect mice against HFD-
induced insulin resistance is therefore unclear (13).
To test whether JIP1-mediated JNK activation is required
for HFD-induced insulin resistance, we examined the effect of
a point mutation in JIP1 that selectively prevents JIP1-induced
JNK activation. It is established that phosphorylation of JIP1
on Thr103 is required for JIP1-mediated JNK activation by the
MLK pathway (25). This requirement of Thr103 phosphoryla-
tion reflects the dynamics of JIP1 function in the activation of
MLK isoforms. JNK phosphorylation of JIP1 on Thr103 causes
the dissociation of bound MLK isoforms that subsequently
become activated by leucine zipper-mediated dimerization and
FIG. 8. Downregulation of the hepatic IL-6 pathway in JIP1TA
mice. (A and B) Chow-fed (ND) and HFD-fed (HF) JIP1WT and
JIP1TA mice (16 weeks) were fasted overnight. The amounts of IL-6
and TNF- in the blood of chow-fed and HFD-fed JIPWT and JIPTTA
mice were examined by ELISA (mean  SE; n  10). Statistically
significant differences between JIPWT and JIPTTA mice are indicated
(**, P  0.01). (C and D) The expression of Socs3 and Vldlr mRNA in
the liver was measured by quantitative RT-PCR analysis of mRNA.
The relative mRNA expression was calculated by normalization of the
data to the amount of Gapdh RNA in each sample (mean  SE; n 
8). Statistically significant differences between JIPWT and JIPTTA mice
are indicated (**, P  0.01; ***, P  0.001). (E) The expression of
SOCS3 and -tubulin in the livers of chow-fed and HFD-fed JIPWT
and JIPTTA mice was measured by immunoblot analysis.
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phosphorylation of the activation loop (25). Loss of JIP1 phos-
phorylation on Thr103 therefore prevents JIP1-mediated JNK
activation by MLK isoforms (25). Here we describe the anal-
ysis of mice with a point mutation in the Jip1 gene that replaces
the JIP1 phosphorylation site Thr103 with Ala. We have shown
that this mutation suppresses HFD-induced JNK activation.
These data demonstrate that JNK activation mediated by the
JIP1 scaffold complex contributes to the response of mice to
being fed an HFD. Indeed, the mutant mice (JIP1TA mice)
exhibited a severe defect in HFD-induced insulin resistance.
The observation that both Jip1/ mice (13) and JIP1TA
mice (this study) exhibit severe defects in HFD-induced JNK
activation and insulin resistance strongly supports the conclu-
sion that a major metabolic role of JIP1 is to activate JNK.
Nevertheless, differences between Jip1/ mice and Jip1TA
mice are apparent. Specifically, Jip1/ mice exhibit a defect in
HFD-induced obesity (13). In contrast, JIP1WT mice and
JIP1TA mice become similarly obese when fed an HFD (Fig.
2A). These data demonstrate that a loss of JIP1-mediated
JNK1 activation (in JIP1TA mice) can phenocopy the effects of
JIP1 deficiency (in Jip1/ mice) on insulin resistance but not
obesity. This conclusion is consistent with the finding that
JNK1 deficiency in peripheral tissues can protect against diet-
induced insulin resistance but not obesity (28–30).
The mechanism of diet-induced obesity suppression in
Jip1/ mice but not JIP1TA mice is unclear. A JNK1-inde-
pendent action of JIP1 may contribute to obesity regulation.
Alternatively, the effects of JIP1 on obesity may be mediated
by a tissue-specific role of JNK1. It is established that JNK1-
regulated obesity is mediated by a central action of JNK1 in the
brain (1, 27), a tissue that expresses four members (JIP1, JIP2,
JIP3, and JIP4) of the JIP protein family that can form het-
erocomplexes (23). The presence of these JIP family proteins
may functionally compensate defects in the brains of JIP1TA
mice, but the more severe defects caused by JIP1 deficiency
may not be fully compensated by other JIP isoforms in the
brains of Jip1/ mice.
A major unresolved question relates to the mechanism of
insulin resistance regulation caused by JIP1-mediated JNK1
activation. Recent studies indicate that hepatic JNK1 (29) and
JNK1-mediated phosphorylation of the adapter protein IRS1
(3) may not cause insulin resistance. In contrast, JNK1 regu-
lation of muscle lipoprotein lipase expression (28), the hypo-
thalamic-pituitary-thyroid axis (1, 27), and adipokines (30)
appear to play important roles in the development of obesity-
induced insulin resistance. A goal for future studies will be to
fully define the mechanism of insulin resistance caused by JNK
activation mediated by the JIP1 scaffold protein pathway.
Conclusions. The JIP1TA mice described in this report ex-
hibit a selective defect in JIP1-mediated JNK activation. These
mice can be used to rigorously test whether JIP1 contributes to
JNK activation in response to a specific stimulus. The results of
the present study demonstrate that the JIP1 scaffold complex
plays a key role in JNK activation caused by feeding of an
HFD. We propose that JIP1TA mice will be useful for future
studies to identify pathways of JNK activation that are medi-
ated by the JIP1 scaffold protein.
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